Assembly Biosciences, Inc. financial data

Symbol
ASMB on Nasdaq
Location
Two Tower Place, 7 Th Floor, South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 211 % -35.5%
Debt-to-equity 282 % +54.6%
Return On Equity -149 % -22.6%
Return On Assets -39 % +9.34%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7.67M shares +20.9%
Common Stock, Shares, Outstanding 7.67M shares +20.9%
Entity Public Float 69M USD +15%
Common Stock, Value, Issued 8K USD +33.3%
Weighted Average Number of Shares Outstanding, Basic 7.66M shares +35.7%
Weighted Average Number of Shares Outstanding, Diluted 7.66M shares +35.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 58.8M USD +17.6%
General and Administrative Expense 18M USD -18.4%
Operating Income (Loss) -43.5M USD +13.9%
Nonoperating Income (Expense) 4.48M USD -16.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -10.2M USD +5.1%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -39M USD +14.6%
Earnings Per Share, Basic -5 USD/shares +36.1%
Earnings Per Share, Diluted -5 USD/shares +36.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 24M USD +25%
Cash, Cash Equivalents, and Short-term Investments 75M USD
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Assets, Current 77.5M USD -31.4%
Property, Plant and Equipment, Net 219K USD -37.2%
Operating Lease, Right-of-Use Asset 2.78M USD +60.7%
Other Assets, Noncurrent 312K USD 0%
Assets 80.8M USD -30%
Accounts Payable, Current 743K USD -7.24%
Employee-related Liabilities, Current 3.04M USD +9.03%
Accrued Liabilities, Current 3.41M USD -5.02%
Contract with Customer, Liability, Current 40.9M USD +23.8%
Liabilities, Current 47.3M USD +14.6%
Contract with Customer, Liability, Noncurrent 13M USD -66.5%
Operating Lease, Liability, Noncurrent 2.35M USD +421%
Liabilities 62.7M USD -22.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -279K USD +4.78%
Retained Earnings (Accumulated Deficit) -845M USD -4.83%
Stockholders' Equity Attributable to Parent 18.1M USD -47.8%
Liabilities and Equity 80.8M USD -30%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -23.4M USD -27.6%
Net Cash Provided by (Used in) Financing Activities 1.92M USD
Net Cash Provided by (Used in) Investing Activities 6.59M USD -61.9%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 7.67M shares +20.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -14.9M USD -1267%
Deferred Tax Assets, Valuation Allowance 212M USD +4.54%
Deferred Tax Assets, Gross 212M USD +4.6%
Operating Lease, Liability 3.09M USD +31.9%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -39M USD +14.5%
Lessee, Operating Lease, Liability, to be Paid 3.93M USD +52.5%
Property, Plant and Equipment, Gross 595K USD -75.5%
Operating Lease, Liability, Current 533K USD -58.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 806K USD -31.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 751K USD -46.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 836K USD +260%
Lessee, Operating Lease, Liability, to be Paid, Year Three 834K USD
Deferred Tax Assets, Operating Loss Carryforwards 132M USD -10.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 5.18M USD +15.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 863K USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 33K USD +3.13%
Deferred Tax Assets, Net of Valuation Allowance 806K USD +24.8%
Share-based Payment Arrangement, Expense 3.09M USD -15.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%